Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID

NCT02153632 | Terminated Phase 3 Results

• 1 other identifier: OS320-3006
• Study Type: interventional
• Target: 135
• Locations: 5 countries
• Sites: 56

Brief Summary

The purpose of this multi-center, randomized, double-blind, parallel-group, 26 week study is to compare the efficacy and safety of two different dose levels of Amantadine Extended Release Tablets to placebo for the treatment of levodopa induced dyskinesia in patients with Parkinson's disease.

Conditions

Parkinson's Disease; Levodopa Induced Dyskinesia (LID)

Keywords

Parkinson's Disease; Levodopa Induced Dyskinesia (LID); LID; Parkinsonism; Dyskinesia

Outcome Measures

Primary Outcomes (1)

• Unified Dyskinesia Rating Scale

  The Unified Dyskinesia Rating Scale is a validated tool for assessment of dyskinesia (involuntary movements) in Parkinson's Disease patients. Rating consists of the change from baseline to Day 98 of the sum of the 26 questions comprising the questionnaire. Each question in the questionnaire is rated on a 5 point scale from 0-4 where 0 is a better outcome. Questions assess: over the past week total hours with dyskinesia and total hours without dyskinesia; problems with speech, chewing and swallowing, eating, dressing, hygiene, handwriting, hobbies, balance, socializing, emotions, spasm or cramps, pain without dystonia and pain from dystonia. The minimum (better) value is 0 and the maximum (worse) value is 130.

  Change from baseline to Day 98

Secondary Outcomes (1)

• Mobility State Self-Assessment - Subject Diary Cards

  Day 14 and Day 98 of treatment

Study Arms (3)

240mg amantadine HCl ER tablets

EXPERIMENTAL

amantadine HCl ER, 240 mg tablets, once daily, 22 weeks

Drug: amantadine HCl ER

320mg amantadine HCl ER tablets

EXPERIMENTAL

amantadine HCl ER, 320 mg tablets, once daily, 22 weeks

Drug: amantadine HCl ER

Placebo Tablets for Amantadine

PLACEBO COMPARATOR

Placebo, tablets, once daily, 26 weeks.

Drug: Placebo

Interventions

amantadine HCl ER DRUG

Subjects are given either 240 mg amantadine HCl ER tablet or 320 mg amantadine HCl ER tablet

Also known as: Osmolex ER Tablet

240mg amantadine HCl ER tablets; 320mg amantadine HCl ER tablets

Placebo DRUG

subjects are given an identical placebo tablet

Also known as: Placebo tablets

Placebo Tablets for Amantadine

Eligibility Criteria

• Age: 30 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed Institutional Review Board (IRB)/ Independent Ethics Committee (IEC) informed consent form.
• Idiopathic Parkinson's disease per the United Kingdom (UK) Parkinson's Disease Society Brain Bank criteria.
• Male or female 30 to 85 years old.
• Levodopa induced, predictable peak-effect dyskinesia considered problematic and/or disabling.
• Screening serum creatinine level within normal range
• On stable doses of all oral anti-Parkinson's medication, including any levodopa preparation, for 30 days and be willing to remain on the same doses throughout the trial.
• The subject/caregiver must demonstrate the ability to complete an accurate home diary based on training and evaluation during the screening period.

You may not qualify if:

• Secondary parkinsonian syndrome, such as vascular, postinflammatory,drug-induced, neoplastic and post-traumatic parkinsonism or any atypical parkinsonian syndrome (e.g., Progressive Supranuclear Palsy, Multi-System Atrophy, etc.);
• Use of amantadine within 14 days before study start, or previously had an adverse event to amantadine
• Currently taking neuroleptics and atypical antipsychotic agents, acetylcholinesterase inhibitors, apomorphine, rimantadine, memantine and dextromethorphan and quinidine if used in combination for treating dyskinesia.
• History of neurosurgical intervention for treating Parkinson's s disease (i.e. pallidotomy or implanted with a deep brain stimulator)
• Any medical condition or past medical history that would increase the risk of exposure to Amantadine HCl Extended Release Tablets or interfere with safety and efficacy evaluations.
• History of cancer within 5 years of screening with following exceptions: adequately treated non-melanomatous skin cancers, localized bladder cancer, non-metastatic prostate cancer or in situ cervical cancer.
• History or current diagnosis of schizophrenia or bipolar disorder;
• Inadequately treated Major Depressive Disorder. Subjects on stable doses of selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) are eligible for the study;
• Is at imminent risk of suicide or had a suicide attempt within 6 months of screening
• History or current diagnosis of Impulse Control Disorder
• Calculated plasma creatinine clearance of \<60 mL/min at screening
• History of or currently has any of the following clinically significant conditions, cardiovascular, respiratory, renal, hepatic, or gastrointestinal disease
• Any clinically significant vital sign, ECG, or laboratory abnormalities;
• A positive test for HIV antibody or history of HIV; hepatitis B surface antigen unless the positive test followed a recent (\<28 days) vaccination for hepatitis B; hepatitis C antibody;
• A positive urine drug test.

Sponsors & Collaborators

• Adamas Pharmaceuticals, Inc.: lead

Study Sites (56)

Unknown Facility

Tucson, Arizona, 85724, United States

Location

Unknown Facility

Fountain Valley, California, 92708, United States

Location

Unknown Facility

Irvine, California, 92602, United States

Location

Unknown Facility

Pasadena, California, 91105, United States

Location

Unknown Facility

Ventura, California, 93001, United States

Location

Unknown Facility

Boulder, Colorado, 80304, United States

Location

Unknown Facility

Hollywood, Florida, 33021, United States

Location

Unknown Facility

Miami, Florida, 40502, United States

Location

Unknown Facility

North Palm Beach, Florida, 33404, United States

Location

Unknown Facility

Sarasota, Florida, 34243, United States

Location

Unknown Facility

Tampa, Florida, 33612, United States

Location

Unknown Facility

Chicago, Illinois, 60612, United States

Location

Unknown Facility

Indianapolis, Indiana, 46202, United States

Location

Unknown Facility

Lexington, Kentucky, 40502, United States

Location

Unknown Facility

Baton Rouge, Louisiana, 70810, United States

Location

Unknown Facility

Ann Arbor, Michigan, 48103, United States

Location

Unknown Facility

Summit, New Jersey, 07901, United States

Location

Unknown Facility

Brooklyn, New York, 11215, United States

Location

Unknown Facility

Patchogue, New York, 11772, United States

Location

Unknown Facility

Raleigh, North Carolina, 27612, United States

Location

Unknown Facility

Columbus, Ohio, 43004, United States

Location

Unknown Facility

Round Rock, Texas, 78681, United States

Location

Unknown Facility

Orem, Utah, 84058, United States

Location

Unknown Facility

Kirkland, Washington, 98033, United States

Location

Unknown Facility

Ottawa, Ontario, Canada

Location

Unknown Facility

Rennes, Ille Et Vilaine, France

Location

Unknown Facility

Amiens, France

Location

Unknown Facility

Bron, 69677, France

Location

Unknown Facility

Clermont-Ferrand, France

Location

Unknown Facility

Créteil, France

Location

Unknown Facility

Lille, France

Location

Unknown Facility

Marseille, 13385, France

Location

Unknown Facility

Montauban, France

Location

Unknown Facility

Nîmes, France

Location

Unknown Facility

Paris, France

Location

Unknown Facility

Poitiers, France

Location

Unknown Facility

Toulouse, France

Location

Unknown Facility

Haag, Bavaria, Germany

Location

Unknown Facility

Erbach im Odenwald, Hesse, Germany

Location

Unknown Facility

Achim, Niedersachesen, Germany

Location

Unknown Facility

Bochum, North Rhine-Westphalia, Germany

Location

Unknown Facility

Hindenburg, State of Berlin, 39596, Germany

Location

Unknown Facility

Weissensee, State of Berlin, Germany

Location

Unknown Facility

Berlin, Germany

Location

Unknown Facility

Wiesbaden, 65191, Germany

Location

Unknown Facility

Würzburg, 97080, Germany

Location

Unknown Facility

L'Hospitalet de Llobregat, Barcelona, 08907, Spain

Location

Unknown Facility

Manresa, Barcelona, Spain

Location

Unknown Facility

Seville, Barcelona, Spain

Location

Unknown Facility

Vallés, Barcelona, Spain

Location

Unknown Facility

Alcorcón, Madrid, Spain

Location

Unknown Facility

Castellana, Madrid, Spain

Location

Unknown Facility

Marañón, Madrid, Spain

Location

Hospital de la Santa Creu i Sant Pau

Barcelona, 08041, Spain

Location

Hospital General de Cataluna

Barcelona, 08195, Spain

Location

Unknown Facility

Pamplona, 31008, Spain

Location

MeSH Terms

Conditions

Parkinson Disease; Parkinsonian Disorders; Dyskinesias

Interventions

Amantadine

Condition Hierarchy (Ancestors)

Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Adamantane; Bridged-Ring Compounds; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals

Results Point of Contact

• Title: George Wagner, VP of Regulatory Affairs
• Organization: Osmotica Pharmaceuticals

gwagner@osmotica.ccom

9088091357

Study Officials

• Angela Dentiste, MBA

  Osmotica Pharmaceutical US LLC

  STUDY CHAIR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 30, 2014
• First Posted: June 3, 2014
• Study Start: July 30, 2014
• Primary Completion: May 20, 2016
• Study Completion: May 20, 2016
• Last Updated: February 16, 2022
• Results First Posted: April 2, 2019

Record last verified: 2022-02

Locations

CA (1); ES (10); US (24); DE (9); FR (12)